Myriad Genetics shares retreat on Court decision
USA Today - 06/13/2013
Investors initially pushed the stock up by focusing on the bright side of the ruling. The Supreme Court said Myriad does have the legal right to patent forms of human’s genetic code that can be predictive of who might contract breast or ovarian cancer, says Michael Bennett, professor of law at Northeastern University. Investors may have been expecting the company to lose all its claims, so the fact were were upheld was a comfort, he says.